Merck resubmits data to FDA for ezetimibe/atorvastatin combo, again

The resubmission of the updated new drug application includes the additional data requested by the FDA, and the company expects the FDA review to be completed in the first half of 2013.

Source: theHeart.org - January 8, 2013 Category: Cardiology Source Type: news